Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, is renowned for its pioneering work in RNA-targeted therapeutics. Founded in 1989, Ionis has established itself as a key player in the pharmaceutical industry, focusing on the development of innovative treatments for a range of serious diseases, including neurological disorders and cardiovascular conditions. With a robust pipeline of drugs, Ionis is particularly noted for its unique antisense technology, which allows for precise modulation of gene expression. This innovative approach has led to significant milestones, including the approval of several groundbreaking therapies. Ionis Pharmaceuticals continues to strengthen its market position through strategic partnerships and a commitment to advancing the field of genetic medicine, making it a notable force in the biopharmaceutical landscape.
DitchCarbon Score
How does Ionis Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ionis Pharmaceuticals's score of 35 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ionis Pharmaceuticals's reported carbon emissions
In 2024, Ionis Pharmaceuticals reported total Scope 1 and 2 greenhouse gas (GHG) emissions of approximately 5,146,000 kg CO2e, reflecting a 6% reduction from the previous year's emissions of about 5,483,000 kg CO2e. The company's Scope 2 emissions, primarily from purchased electricity, accounted for about 2,530,000 kg CO2e in 2024, down from approximately 2,788,000 kg CO2e in 2023. Ionis has set a near-term target to continue reducing its GHG emissions, achieving a 6% decrease in both Scope 1 and 2 emissions from 2023 to 2024. The emissions intensity for Scope 1 and 2 was reported at about 4,870 kg CO2e per employee in 2024, compared to approximately 6,110 kg CO2e per employee in 2023. The company does not currently disclose Scope 3 emissions data, indicating a focus on direct and indirect emissions from its operations. Ionis Pharmaceuticals is committed to ongoing climate initiatives, as evidenced by its consistent reporting and reduction targets, which align with industry standards for corporate responsibility and sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 2,566,000,000 | - | - | - |
| Scope 2 | 2,052,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ionis Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
